Peruvian economic watchdog INDECOPI has issued fines on five major drug store chains, having determined their involvement in a price-fixing scheme affecting 36 major medications, violating competition legislation and adversely affecting consumers.
Charges were presented against the Arcangel (Albis SA), Fasa (Farmacias Peruanas SA), Inkafarma (Eckerd Perú SA), Mifarma (Mifarma SA) and Felicidad (Nortfarma SAC) drug store chains, with fines totalling approximately $2,641,992 USD for their involvement in actions classed as ‘anticompetitive’ by Peru’s antitrust legislation.
As well as the economic sanctions mentioned, INDECOPI’s Commission for the Defense of Free Competition (CLC) has ordered the companies to design and implement a three-year program to avoid any relapse into uncompetitive behavior, including special training for sales personnel.
Full Content: Kaos en la Red
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI